Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

This study has been completed.

Sponsor:

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00020111

First received: July 11, 2001

Last updated: May 14, 2011

Last verified: February 2005

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC. Phase I trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia including acute promyelocytic leukemia or lymphoma A collaborative study of The Pediatric Oncology Branch, National Cancer Institute and the Children's Oncology Group. Blood. 2007 Oct 24; [Epub ahead of print]

Fox E, Adamson PC, Murgo A, et al.: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children with refractory leukemia. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1582, 2002.

To Top